The concern of generic competition has long loomed around copyright’s iconic drug, Sildenafil, raising questions about the future of related drug investments. While early times saw substantial profits, the exclusivity expiration has allowed the door for less expensive substitutes, likely reducing earnings and creating a significant danger for sta